Brind.

Dynavax Technologies announced the UK approval of HEPLISAV-B and confirmed participation in the Wells Fargo Healthcare Conference.

2 reports, 1 independent Updated Aug 28
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Dynavax Technologies announced the UK approval of HEPLISAV-B and confirmed participation in the Wells Fargo Healthcare Conference.

Who's involved

What this event is mainly about
Dynavax Technologies (United States)

How it developed

Newest first. Tap a step to see who reported it.
  1. Dynavax's HEPLISAV-B received UK approval and the company will attend the Wells Fargo Healthcare Conference.1 source
  2. DVAX reported record revenue for HEPLISAV-B and benefits from Trump-era tariffs and onshoring.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • PR NewswireDynavax to Participate in the 2025 Wells Fargo Healthcare Conference EMERYVILLE, Calif., Aug. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceu
  • Unknown outlet